Molecular Biology Reports

, Volume 37, Issue 3, pp 1191–1195

High Mobility Group Box 1: a potential therapeutic target for systemic lupus erythematosus

  • Hai-Feng Pan
  • Guo-Cui Wu
  • Wei-Ping Li
  • Xiang-Pei Li
  • Dong-Qing Ye
Article

DOI: 10.1007/s11033-009-9485-7

Cite this article as:
Pan, HF., Wu, GC., Li, WP. et al. Mol Biol Rep (2010) 37: 1191. doi:10.1007/s11033-009-9485-7

Abstract

High Mobility Group Box 1 (HMGB1) is a nuclear protein participating in chromatin architecture and transcriptional regulation. Recently, there is increasing evidence that HMGB1 contributes to the pathogenesis of chronic inflammatory and autoimmune diseases due to its pro-inflammatory and immunostimulatory properties. Elevated expression of HMGB1 was found in the sera of patients and mice with systemic lupus erythematosus (SLE). In addition, it has been shown that HMGB1 may act as a proinflammatory mediator in antibody-induced kidney damage in SLE. All theses findings suggest that HMGB1 have important biological effects in autoimmunity that might be a promising therapeutic target for SLE. In this review, we will briefly discuss the biological features of HMGB1 and summarize recent advances on the role of HMGB1 in the pathogenesis and treatment of SLE.

Keywords

Autoantibodies Autoimmune HMGB1 Nucleosomes Systemic lupus erythematosus Therapeutic target 

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Hai-Feng Pan
    • 1
  • Guo-Cui Wu
    • 2
  • Wei-Ping Li
    • 2
  • Xiang-Pei Li
    • 3
  • Dong-Qing Ye
    • 1
  1. 1.Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical UniversityHefeiPeople’s Republic of China
  2. 2.Department of PharmacologyAnhui Medical UniversityHefeiPeople’s Republic of China
  3. 3.Department of RheumatologyAnhui Provincial HospitalHefeiPeople’s Republic of China

Personalised recommendations